Senseonics (NYSE:SENS) Now Covered by Analysts at Barclays

Key Points

• Analysts at Barclays have initiated coverage on Senseonics (NYSE:SENS) with an "overweight" rating and set a price target of $1.50, indicating a potential upside of 226.09% from its previous close.
• Other firms have varied ratings, with Wall Street Zen issuing a "sell" and Lake Street Capital a "strong-buy," contributing to a consensus rating of "Strong Buy" and a target price of $1.54.
• In recent institutional trading activity, Bank of America Corp DE significantly increased its holdings in Senseonics by 1,282.4%, now owning over 915,000 shares.

Equities research analysts at Barclays began coverage on shares of Senseonics (NYSE:SENS - Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The brokerage set an "overweight" rating and a $1.50 price target on the stock. Barclays's price objective points to a potential upside of 233.33% from the stock's current price.

SENS has been the topic of several other research reports. TD Cowen started coverage on Senseonics in a research note on Tuesday, July 15th. They issued a "buy" rating and a $1.25 price objective on the stock. Wall Street Zen upgraded Senseonics to a "sell" rating in a research note on Monday, May 12th. HC Wainwright restated a "buy" rating and issued a $1.40 price objective (up from $1.10) on shares of Senseonics in a report on Tuesday, July 8th. Finally, Lake Street Capital upgraded shares of Senseonics to a "strong-buy" rating in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $1.54.

Senseonics Price Performance

SENS stock traded down $0.01 during trading on Wednesday, hitting $0.45. 2,900,736 shares of the company's stock traded hands, compared to its average volume of 8,010,561. The stock has a market capitalization of $366.61 million, a price-to-earnings ratio of -3.45 and a beta of 0.93. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The business has a fifty day simple moving average of $0.50 and a 200 day simple moving average of $0.60. Senseonics has a 52 week low of $0.25 and a 52 week high of $1.40.

Institutional Investors Weigh In On Senseonics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in Senseonics during the 4th quarter valued at about $720,000. Raymond James Financial Inc. purchased a new position in shares of Senseonics during the fourth quarter valued at approximately $26,000. Northern Trust Corp grew its stake in shares of Senseonics by 11.2% during the fourth quarter. Northern Trust Corp now owns 1,194,960 shares of the company's stock valued at $625,000 after buying an additional 120,441 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Senseonics by 6,694.1% in the fourth quarter. Jane Street Group LLC now owns 6,118,786 shares of the company's stock worth $3,203,000 after buying an additional 6,028,726 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of Senseonics by 299.0% in the fourth quarter. Millennium Management LLC now owns 1,088,029 shares of the company's stock worth $569,000 after buying an additional 815,332 shares during the period. Hedge funds and other institutional investors own 12.36% of the company's stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.